A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Clazakizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Vitaeris
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 May 2015 According to Alder BioPharmaceuticals media release, data will be presented at a future rheumatology society meeting.
- 05 May 2015 Results published in an Alder Biopharmaceuticals media release.